Recruiting Trials
This page includes information about clinical trials from IAS partners who are currently recruiting sites or participants. Interested parties should contact the coordinating organization directly.
Arrowhead Pharmaceuticals
YOSEMITE for People Living with Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals has a Phase 3, double-blind, placebo-controlled study to evaluate the efficacy and safety of zodasiran in adolescent and adult patients with homozygous familial hypercholesterolemia (HoFH) (YOSEMITE). Zodasiran is a synthetic, double-stranded, hepatocyte-targeted ribonucleic acid interference (RNAi) trigger designed to specifically silence expression of ANGPTL3 mRNA. Study treatment (zodasiran or placebo) is administered subcutaneously at five timepoints over a 12 month period. Enrollment into YOSEMITE will be open to participants 12 years and older with an established diagnosis of HoFH, who are willing to remain on a stable diet and stable background lipid-lowering therapy during the 12-month, double-blind, placebo-controlled, randomized (2:1) treatment period.
If you are a clinician and would like more information about YOSEMITE, please contact Arrowhead Pharmaceuticals at YOSEMITE@arrowheadpharma.com.
Promoting the scientific understanding of atherosclerosis
Newsletters
-
The IAS e-Newsletter is a digest of the latest from the IAS and its Constituent Member Societies.
-
Going beyond statins, this resource provides the latest information about primary prevention for clinicians.
